Inclusion Criteria:

- Histologically proven adenocarcinoma of the stomach or gastroesophageal junction
without gross or microscopic evidence of residual disease after surgery with curative
intent;

- Subtotal or total gastrectomy with at least D1 dissection;

- Gastroesophageal junction adenocarcinoma extending to the stomach with the center
lying 2 to 5 cm below the anatomic esophago-gastric junction;

- Patients with nodal involvement (pN+) or patients without nodal involvement (pN0)
with pT2b-3-4. It is recommended to examine at least 15 lymph nodes;

- Age between 18 and 75 years;

- ECOG performance status 0-1;

- No previous chemotherapy and/or radiotherapy;

- Complete staging procedures within 3 months prior to randomization;

- Laboratory requirement (within 8 days prior to randomization):

- Haematology (Neutrophils > 2.0 x 109 /L, Platelet > 100 x 109 /L, Hemoglobin >
10g/dL);

- Hepatic function (Total bilirubin < 1 UNL, ASAT (SGOT) and ALAT (SGPT) <
2.5xUNL, Alkaline phosphatase < 2.5xUNL. Patients with ASAT or ALAT > 1.5xUNL
associated with alkaline phosphatase > 2.5XUNL are not eligible.)

- Renal function (Creatinine < 1.5 UNL. In presence of borderline values, the
calculated creatinine clearance according to Cockroft-Gault formula, 60 ML/min.

- Recovery from acute effects of surgery. The first infusion of study chemotherapy
should be administered 3 to 8 weeks after surgery treatment;

- Written informed consent signed and dated before randomization procedures, including
expected cooperation of the patients for the treatment and follow-up, must be
obtained and documented according to the local regulatory requirement.

Exclusion Criteria:

- Non-radical surgery as assessed microscopically (no tumor-free margin of resection,
positive biopsy of peritoneal suspicious lesions);

- Synchronous metastases, even curatively resected;

- Pregnant or lactating patients; patients with reproductive potential must implement
adequate contraceptive measures;

- Prior or concurrent history of:

- positive HIV serology,

- chronic diarrhoea,

- chronic bowel inflammation or subobstruction,

- neoplasm other than gastric cancer, except for: curatively treated non-melanoma
skin cancer, in situ carcinoma of the cervix,

- previous history of myocardial infarction within 1 year from study entry,

- hypersensitivity reaction to polysorbate 80;

- Presence of other systemic disease limiting drug administration and influencing
patient survival:

- uncontrolled hypertension,

- high-risk uncontrolled arrhythmia,

- unstable angina pectoris;

- Symptomatic

- peripheral neuropathy,

- altered hearing > 2 grade by NCIC-CTG criteria;

- Active uncontrolled infection.

- Definite contra-indications for the use of corticosteroids: unstable diabetes
mellitus, active peptic ulcer;

- Concurrent administration of:

- corticosteroids or equivalent except as use for the prophylactic medication
regimen, treatment of acute hypersensitivity reactions or unless chronic
treatment (initiated > 6 months prior to study entry) at low doses (< 20mg
methylprednisolone or equivalent);

- any other experimental drug under investigation: concurrent treatment with any
other anticancer therapy, growth factors with preventive intent